Shelby Knowles / Bloomberg via Getty Images Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for sleep apnea last month. Weight loss ...

From Alzheimer's prevention to weight-loss dominance, Novo bets on innovation and share repurchases amid Medicare pressure.

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

As the next round of Medicare drug pricing negotiations get underway, experts predict President Trump may seek to weaken the program.

Novo Nordisk stock falls as Medicare selects its marketed semaglutide medicines catering to T2D and obesity for price ...

Medicare drug plans can now cover Eli Lilly & Co.’s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that’s expected to prove a big boost for the drug company.

Despite online claims, President Donald Trump’s executive orders did not include removing Medicare’s $35 monthly out-of-pocket price cap, which is set by law.

A letter from several Democratic Senators urged Trump to use his deal-making skills to “flat out reject any request to end ...

Parkview Health placed in the Top 10% on the most recent RAND Corp. list of the highest relative prices medical providers ...

The founder, managing principal, and chief investment officer of AQR Capital Management, […] Eli Lilly and Company ( NYSE:LLY ) will increase its dividend from last year's comparable payment on the ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

Democrat U.S. Senators Urge President Trump to Reject Big Pharma’s Push to End Medicare Price Negotiations, Protect Medicare Enrollees ...